

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.**

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/APTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/705,459	
		Filing Date	November 12, 2003	
		First Named Inventor	BARNEA Eilon et al	
		Group Art Unit	1644	
		Examiner Name	/Marianne Dibrino/	
Sheet		Of	Attorney Docket Number	26884
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
MD	10	Hunt et al. "Characterization of Peptides Bound to Class I MHC Molecule HLA-A2.1 by Mass-Spectrometry", Science, 255(5049): 1261-1263, 1992.		
	11	Cox et al. "Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines", Science, 264(5159): 716-719, 1994.		
	12	Zarling et al. "Phosphorylated Peptides Are Naturally Processed and Presented by Major Histocompatibility Complex Class I Molecules in Vivo", Journal of Experimental Medicine, 192(12): 1755-1762, 2000.		
	13	Flad et al. "Direct Identification of Major Histocompatibility Complex Class I-Bound Tumor-Associated Peptide Antigens of a Renal Carcinoma Cell Line by a Novel Mass Spectrometric Method", Cancer Research, 58(24): 5803-5811, 1998.		
	14	Li et al. "Frequent Methylation of Estrogen Receptor in Prostate Cancer: Correlation With Tumor Progression", Cancer Res., 60: 702-706, 2000.		
	15	Baldwin "Antibodies to Fetal Antigens Associated With Rodent Tumours", Ciba Found Symp., 96: 230-241, 1983. Abstract.		
	16	Belinsky et al. "A Microassay For Measuring Cytosine DNA Methyltransferase Activity During Tumor Progression", Toxicol Lett., 82-83: 335-340, 1995. Abstract.		
	17	Belinsky et al. "Increased Cytosine DNA-Methyltransferase Activity Is Target-Cell-Specific and an Early Event in Lung Cancer", Proc. Natl. Acad. Sci., 93(9): 4045-4050, 1996. Abstract.		
	18	Biran et al. "On the Oncodevelopmental Role of Human Imprinted Genes", Med. Hypotheses, 43(2): 119-123, 1994. Abstract.		
	19	Coggin "Embryonic Antigens in Malignancy and Pregnancy: Common Denominators in Immune Regulation", Ciba Found Symp., 96: 28-54, 1983. Abstract.		
	20	Eisenbach et al. "Antitumor Vaccination Using Peptide Based Vaccines", Immunol. Lett., 74(1): 27-34, 2000. Abstract.		
	21	El-Deiry et al. "High Expression of the DNA Methyltransferase Gene Characterizes Human Neoplastic Cell and Progression Stages of Colon Cancer", Proc. Natl. Acad. Sci., 88(8): 3470-3474, 1991. Abstract.		
	22	Jager et al. "Vaccination for Malignant Melanoma: Recent Development", Oncology, 60(1): 1-7, 2001. Abstract.		
	23	Knutson et al. "Expansion of HER2/Neu-Specific T Cells Ex Vivo Following Immunization With a HER2/Neu Peptide-Based Vaccine", Clin. Breast Cancer, 2(1): 73-79, 2001. Abstract.		
	24	Pilat et al. "Examination of the DNA Methylation Properties in Nontumorigenic and Tumorigenic Breast Epithelial Cell Lines", Anticancer Res., 18(4A): 2575-2582, 1998. Abstract.		
	25	Sinkovics et al. "Vaccination Against Human Cancer (Review)", Int. J. Oncol., 16(1): 81-96, 2000. Abstract.		
	26	Szyf "The DNA Methylation Machinery as a Target for Anticancer Therapy", Pharmacol. Ther., 70(1): 1-37, 1996. Abstract.		
	27	Szyf "Targeting DNA Methyltransferase in Cancer", Cancer Metastasis Rev., 17(2): 219-231, 1998. Abstract.		
	28	Wiesmuller et al. "Peptide Vaccines and Peptide Libraries", Biol. Chem., 382(4): 571-579, 2001. Abstract.		
MD	29	Barnea et al. "Analysis of Endogenous Peptides Bound by Soluble MHC Class I Molecules: A Novel Approach for Identifying Tumor-Specific Antigens", Eur. J. Immunol., 32: 213-222, 2002.		

MD	30	Zappacosta et al. "The Murine Liver-Specific Nonclassical MHC Class I Molecule Q10 Binds a Classical Peptide Repertoire", The Journal of Immunology, 164: 1906-1915, 2000.	
MD	31	Niederreither et al. "Expression of T:G Mismatch-Specific Thymidine-DNA Glycosylase and DNA Methyl Transferase Genes During Development and Tumorigenesis", Database Medline, DN 99008337, Oncogene, 17(12): 1577-1585, 1998. Abstract.	
MD	32	Berg et al. "A Novel DNA Methyl Transferase I-Derived Peptide Eluted From Soluble HLA-A*0201 Induces Peptide-Specific Tumor Directed Cytotoxic T Cells", Dep.of Internal Medicine, Iowa (USA) & The Smoler Protein Center, Dep. of Biology, Haifa (IL), P. 1-40, 2003.	

Signature	/Marianne Dibrino/	Considered	02/16/2007
-----------	--------------------	------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.